Creo Medical Group PLC

LSE:CREO (UK)  
£ 0.37 (+1.39%) Jun 7
At Loss
P/B:
2.20
Market Cap:
£ 131.94M ($ 167.76M)
Enterprise V:
£ 121.74M ($ 154.79M)
Volume:
336.33K
Avg Vol (2M):
642.20K
Also Trade In:
Volume:
336.33K
At Loss
Avg Vol (2M):
642.20K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Creo Medical Group PLC ( LSE:CREO ) from 2016 to Jun 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Creo Medical Group PLC stock (LSE:CREO) PE ratio as of Jun 10 2024 is 0. More Details

Creo Medical Group PLC (LSE:CREO) PE Ratio (TTM) Chart

To

Creo Medical Group PLC (LSE:CREO) PE Ratio (TTM) Historical Data

Total 1279
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Creo Medical Group PLC PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-10 At Loss 2024-04-04 At Loss
2024-06-07 At Loss 2024-04-03 At Loss
2024-06-06 At Loss 2024-04-02 At Loss
2024-06-05 At Loss 2024-03-28 At Loss
2024-06-04 At Loss 2024-03-27 At Loss
2024-06-03 At Loss 2024-03-26 At Loss
2024-05-31 At Loss 2024-03-25 At Loss
2024-05-30 At Loss 2024-03-22 At Loss
2024-05-29 At Loss 2024-03-21 At Loss
2024-05-28 At Loss 2024-03-20 At Loss
2024-05-24 At Loss 2024-03-19 At Loss
2024-05-23 At Loss 2024-03-18 At Loss
2024-05-22 At Loss 2024-03-15 At Loss
2024-05-21 At Loss 2024-03-14 At Loss
2024-05-20 At Loss 2024-03-13 At Loss
2024-05-17 At Loss 2024-03-12 At Loss
2024-05-16 At Loss 2024-03-11 At Loss
2024-05-15 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-03-01 At Loss
2024-05-07 At Loss 2024-02-29 At Loss
2024-05-03 At Loss 2024-02-28 At Loss
2024-05-02 At Loss 2024-02-27 At Loss
2024-05-01 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss

Creo Medical Group PLC (LSE:CREO) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from Europe and the rest from the United Kingdom and the rest of the world.